A World Health Organization study looked at several drugs touted to treat COVID-19 and found that Gilead’s remdesivir “had no substantial effect on a COVID-19 patient’s chance of survival,” ZeroHedge reports.
The study also showed the drug made no difference in the length of a patient’s hospital stay, either. Gilead, on the other hand, disagreed, saying: "The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies validating the clinical benefit of [remdesivir].”
The WHO also looked at hydroxychloroquine, lopnavir and interferon regimes and found them ineffective as well.
SOURCE: ZeroHedge October 15, 2020